Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.58 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | MAOA | P21397 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5432585 | 0.84 | TYR (0.57) | HSD11B1HTR2BLMNAMAOBMMP1 | |
| SCHEMBL5436045 | 0.82 | MAPT (0.53) | HTR2BGRIN1GRIN2BLMNAMAOA | |
| SCHEMBL5426867 | 0.82 | HTR2B (0.48) | HTR2BLMNAMAOAMAOBALDH1A1 | |
| SCHEMBL5425527 | 0.82 | CYP1A2 (0.58) | HTR2BGRIN1GRIN2BLMNAMAOA | |
| SCHEMBL1949536 | 0.81 | MAPT (0.55) | TNFRSF1AHTR2BGRIN1GRIN2BLMNA | |
| SCHEMBL5433146 | 0.81 | HTR2B (0.54) | HSD11B1HTR2BGRIN1GRIN2BCYP1A1 | |
| SCHEMBL5432257 | 0.81 | CYP1A2 (0.62) | HTR2BGRIN1GRIN2BMAOAMAOB | |
| SCHEMBL5441731 | 0.80 | NFE2L2 (0.52) | HTR2BMAOAMAOBALDH1A1CYP1A1 | |
| Hydrochloric Acid SCHEMBL5427451 | 0.80 | HTR2B (0.56) | TNFRSF1AHTR2BGRIN1GRIN2BLMNA | |
| SCHEMBL5431012 | 0.79 | HDAC2 (0.56) | HTR2BLMNATP53ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2617709-B1 | Guanidine derivatives as antiviral agents | BIOTRON LTD (AU) | 2022-11-16 | — | — | EP | claimed |
| US-10472332-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2019-11-12 | — | — | US | claimed |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2017-09-14 | — | — | US | claimed |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2015-11-05 | — | — | US | claimed |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | GAGE PETER WILLIAM (AU) | 2013-02-07 | — | — | US | claimed |
| US-20070099968-A1 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2007-05-03 | — | — | US | claimed |
| EP-1646371-A2 | ANTIVIRAL COMPOUNDS AND METHODS | Biotron Limited (AU) | 2006-04-19 | — | — | EP | claimed |
| WO-2004112687-A2 | ANTIVIRAL ACYLGUANIDINE COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2004-12-29 | — | — | WO | claimed |
| EP-2617709-B1 | Guanidine derivatives as antiviral agents | BIOTRON LTD (AU) | 2022-11-16 | — | — | EP | disclosed |
| US-11192863-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2021-12-07 | — | — | US | disclosed |
| US-10472332-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2019-11-12 | — | — | US | disclosed |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2017-09-14 | — | — | US | disclosed |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2015-11-05 | — | — | US | disclosed |
| EP-2617709-A1 | Guanidine derivatives as antiviral agents | Biotron Limited (AU) | 2013-07-24 | — | — | EP | disclosed |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | GAGE PETER WILLIAM (AU) | 2013-02-07 | — | — | US | disclosed |
| US-20070099968-A1 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192863-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | HSD11B1 2826/4885TNFRSF1A 3672/4885HTR2B 4140/4885 |
| US-10472332-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | HSD11B1 2826/4885TNFRSF1A 3672/4885HTR2B 4140/4885 |
| US-20070099968-A1 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | HSD11B1 2483/4885TNFRSF1A 3646/4885HTR2B 4329/4885 |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | HSD11B1 2826/4885TNFRSF1A 3672/4885HTR2B 4140/4885 |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | HSD11B1 2829/4885TNFRSF1A 3643/4885HTR2B 4247/4885 |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | HSD11B1 2829/4885TNFRSF1A 3643/4885HTR2B 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.